Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 144 participants.

Also called NCT06712615

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 144 participants (planned count) (from the registry)
Sponsor
ProGen. Co., Ltd. (from the registry)
Registry
  • NCT NCT06712615
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06712615. Randomized; double masking; primary purpose treatment. Start 2024-12-05 (actual); primary completion 2025-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus (T2DM)
Condition
Obesity Type 2 Diabetes Mellitus
Intervention (Biological)
PG-102
Intervention (Other)
Placebo
Lead sponsor
ProGen. Co., Ltd. (class: other)

Record details

Record id
cardio:ct-nct06712615
Content hash
b6ebb3568ffa85f79e47daa49c5662486d3bcd9da7d979d80ed88b76b96e2e80